Chemotherapeutic agents as well as targeted agents for the treatment of bronchial lung cancer can be used together. It has been shown that concomitant use of chemotherapeutic agents and targeted agents can prolong the survival of patients with advanced bronchopulmonary cancer.
The chemotherapeutic agents for bronchial lung cancer are generally the following: platinum, anti-folate, anti-pyrimidine, purple shirt, anthracycline, chymopapain, nitrosoureas, and others. And the targets of targeted drug therapy are usually EGFR (epidermal growth factor receptor) mutation, ALK (mesenchymal lymphoma kinase) rearrangement, Her2 (human epidermal growth factor receptor-2) mutation, ROS1 (reactive oxygen species) fusion, and BRAF mutation. For patients with intermediate to advanced bronchopulmonary cancer who have lost the opportunity for surgery, systemic chemotherapy, or targeted therapy is an option.
Targeted therapy combined with chemotherapy has been shown to significantly improve the effectiveness of advanced chemotherapy for non-small cell lung cancer, prolonging the median time to tumor progression and extending patient survival. For patients whose physical and economic conditions allow, targeted therapy combined with chemotherapy regimens can be used. However, the specific regimen needs to be decided by the clinician according to the patient’s specific situation.